Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEI890)

Drug Name
FV-Aib-TDVGPFAF Drug Info
Synonyms [Aib29,Asp31,Pro34,Phe35]CGRP(27-37)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44406785
TTD Drug ID
DMEI890

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Calcitonin gene-related peptide receptor (CGRPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ubrogepant DM749I3 Migraine 8A80 Approved [3]
Fremanezumab DMDZY54 Hyperprolactinaemia 5A60.1 Approved [4]
Galcanezumab DMIZ1E8 Hyperprolactinaemia 5A60.1 Approved [4]
Erenumab DMWMCN0 Hyperprolactinaemia 5A60.1 Approved [4]
Rimegepant DMHOAUG Migraine 8A80 Approved [5]
MK-3207 DM6OLGC Migraine 8A80 Phase 2 [6]
AMG 334 DMI3WFG Migraine 8A80 Phase 2 [7]
Telcagepant DMFT5D6 Cluster headache 8A81.0 Phase 2 [8]
Olcegepant DMVW5KR Migraine 8A80 Phase 2 [9]
BI-44370 DMZR9OU Migraine 8A80 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Calcitonin gene-related peptide 1 (CALCA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cizolirtine DMOFTRE Neuropathic pain 8E43.0 Phase 2 [11]
Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2 DM19NMF Discovery agent N.A. Investigative [1]
Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2 DM9W21L Discovery agent N.A. Investigative [1]
VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 DMJ2PG1 Discovery agent N.A. Investigative [1]
Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2 DM3BUP6 Discovery agent N.A. Investigative [1]
Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2 DMO0W9V Discovery agent N.A. Investigative [1]
Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 DMSMVK4 Discovery agent N.A. Investigative [1]
Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 DMR1N53 Discovery agent N.A. Investigative [1]
Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2 DMKO982 Discovery agent N.A. Investigative [1]
Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2 DMJU4AM Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin gene-related peptide 1 (CALCA) TTVSFJW CALCA_HUMAN Inhibitor [1]
Calcitonin gene-related peptide receptor (CGRPR) TTY6O0Q CALRL_HUMAN Inhibitor [2]

References

1 Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97.
2 Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
7 EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.
8 CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5.
9 Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74.
10 BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84.
11 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.